Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 50/100

Failure Rate

14.3%

1 terminated/withdrawn out of 7 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

57%

4 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

3 recruiting

Enrollment Performance

Analytics

Phase 3
2(40.0%)
Phase 4
2(40.0%)
Phase 2
1(20.0%)
5Total
Phase 3(2)
Phase 4(2)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials
NCT07195591Phase 3Recruiting

Beginning Radiation Immediately With GammaTile at GBM Excision Versus Standard of Care

Role: lead

NCT04427384Recruiting

Registry of Patients With Brain Tumors Treated With STaRT (GammaTiles)

Role: lead

NCT04690348Phase 2Recruiting

Intracavitary Carrier-embedded Cs131 Brachytherapy for Recurrent Brain Metastases: a Randomized Phase II Study

Role: collaborator

NCT04365374Phase 3Active Not Recruiting

Post-Surgical Stereotactic Radiotherapy (SRT) Versus GammaTile-ROADS (Radiation One and Done Study)

Role: lead

NCT05342883Phase 4Active Not Recruiting

GammaTile and Stupp in Newly Diagnosed GBM

Role: lead

NCT05900908Phase 4Withdrawn

Post-operative Adjuvant Therapy w/wo GammaTile + Systemic Therapy

Role: lead

NCT03088579Completed

Intraoperative Brachytherapy for Central Nervous System Lesions: A Validation Study of a Radioactive Seed Loading Device

Role: collaborator

All 7 trials loaded